Joint prediction of glioma molecular marker status based on GDI-PMNet

Determining the status of glioma molecular markers is a problem of clinical importance in medicine. Current medical-imaging-based approaches for this problem suffer from various limitations, such as incomplete fine-grained feature extraction of glioma imaging data and low prediction accuracy of molecular marker status.

To address these issues, a deep learning method is presented for the simultaneous joint prediction of multi-label statuses of glioma molecular markers. Firstly, a Gradient-aware Spatially Partitioned Enhancement algorithm (GASPE) is proposed to optimize the glioma MR image preprocessing method and to enhance the local detail expression ability; secondly, a Dual Attention module with Depthwise Convolution (DADC) is constructed to improve the fine-grained feature extraction ability by combining channel attention and spatial attention; thirdly, a hybrid model PMNet is proposed, which combines the Pyramid-based Multi-Scale Feature Extraction module (PMSFEM) and the Mamba-based Projection Convolution module (MPCM) to achieve effective fusion of local and global information; finally, an Iterative Truth Calibration algorithm (ITC) is used to calibrate the joint state truth vector output by the model to optimize the accuracy of the prediction results.

Based on GASPE, DADC, ITC and PMNet, the proposed method constructs the Gradient-Aware Dual Attention Iteration Truth Calibration-PMNet (GDI-PMNet) to simultaneously predict the status of glioma molecular markers (IDH1, Ki67, MGMT, P53), with accuracies of 98.31%, 99.24%, 97.96% and 98.54% respectively, achieving non-invasive preoperative prediction, thereby capable of assisting doctors in clinical diagnosis and treatment.

The GDI-PMNet method demonstrates high accuracy in predicting glioma molecular markers, addressing the limitations of current approaches by enhancing fine-grained feature extraction and prediction accuracy. This non-invasive preoperative prediction tool holds significant potential to assist clinicians in glioma diagnosis and treatment, ultimately improving patient outcomes.